Savara Inc (NASDAQ:SVRA - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 552,135 shares changed hands during trading, a decline of 30% from the previous session's volume of 793,033 shares.The stock last traded at $5.07 and had previously closed at $5.07.
Analysts Set New Price Targets
SVRA has been the subject of several recent research reports. JMP Securities began coverage on Savara in a report on Thursday, February 15th. They set an "outperform" rating and a $8.00 target price for the company. Piper Sandler boosted their price objective on Savara from $7.00 to $16.00 and gave the company an "overweight" rating in a research report on Monday, March 4th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara has an average rating of "Buy" and a consensus target price of $8.20.
Get Our Latest Report on Savara
Savara Trading Down 0.6 %
The firm's 50-day simple moving average is $4.96 and its 200 day simple moving average is $4.37. The stock has a market cap of $696.27 million, a P/E ratio of -15.27 and a beta of 0.77. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19.
Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. As a group, equities research analysts anticipate that Savara Inc will post -0.38 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. increased its stake in Savara by 30.9% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company's stock valued at $30,008,000 after buying an additional 1,874,000 shares during the period. Jennison Associates LLC increased its stake in shares of Savara by 44.6% during the third quarter. Jennison Associates LLC now owns 3,866,762 shares of the company's stock valued at $14,616,000 after acquiring an additional 1,192,730 shares during the period. Vivo Capital LLC acquired a new position in shares of Savara during the third quarter valued at approximately $7,232,000. Polar Capital Holdings Plc bought a new stake in Savara during the third quarter worth approximately $3,780,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Savara in the fourth quarter worth approximately $74,000. 87.93% of the stock is owned by institutional investors and hedge funds.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Stories
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
